GNCAQ — Genocea Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$12.49m
- $1.64m
NASDAQ RESUMED
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE
Brief: Genocea’S Gen-009 Clinical Results Presentation Selected By Asco’S Journal Of Clinical Oncology As A Top 10 Featured Immuno-Oncology Abstract
Brief: Genocea Biosciences Inc - Filed A Certificate Of Amendment To Co's Restated Certificate Of Incorporation To Effect A Reverse Stock Split
Brief: Genocea Announces Research Collaboration With Iovance
Brief: Genocea Announces Positive Interim Immunogenicity Data From Gen-009 Neoantigen Vaccine Phase 1/2A Clinical Trial
Brief: Genocea Reports First-Quarter 2019 Financial Results
Brief: Genocea Biosciences Files Prospectus Related To Resale Or Other Disposition Of Up To 76.95 Mln Shares
Brief: Genocea Names Diantha Duvall As CFO
Brief: Glaxosmithkline PLC Reports 12.7% Passive Stake In Genocea Biosciences Inc As Of February 14 - SEC Filing
Brief: New Enterprise Associates 16, L.P. Reports 49.1 Percent Stake In Genocea Biosciences Inc As Of Feb 14
Brief: Genocea Announces Private Placement Financing Of Up To $39 Mln
Brief: Genocea Biosciences-On Dec 17, Listing Of Shares Of Co's Common Stock Will Be Transferred From Nasdaq Global Market To Nasdaq Capital Market
Brief: Cofactor Genomics To Evaluate Use Of Immunoprism Assay In Genocea's Clinical Trial Of Gen-009
Advisory: Alert on Genocea Biosciences' quarterly revenue withdrawn
Advisory: Alert on Genocea Biosciences' quarterly revenue withdrawn
Brief: Genocea Biosciences Reports Quarterly Loss Per Share $0.09
Advisory: Alert on Genocea Biosciences' quarterly revenue withdrawn
Brief: Genocea Biosciences Inc QTRLY Loss Per Share $0.05